A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer

Inclusion Criteria: * Previously untreated patients with pathologically proven advanced gastric adenocarcinoma with regional LN metastasis (clinical stage: cT2-4 and N+) * At least one measurable regional lymph node metastasis according to the Response Evaluation Criteria in Solid Tumors (RECIST v. 1.0) * age between 18 and 75 years * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 * no prior chemotherapy or radiotherapy * adequate bone marrow, hepatic and renal function (absolute neutrophil count \[ANC\] ≥ 1.5ⅹ109/L, platelet count ≥ 100ⅹ109/L, total bilirubin ≤ 1.5ⅹupper limit of normal \[ULN\], serum transaminases ≤ 2.5ⅹULN, alkaline phosphatase ≤ 2.5ⅹULN, serum creatinine ≤ 1.5ⅹULN or actual or calculated creatinine clearance ≥ 50 mL/min). Exclusion Criteria: * clinical stage T1 tumors * clinical or radiologic evidence of distant metastasis * intestinal obstruction or impending obstruction * active tumor bleeding * interstitial pneumonitis or symptomatic pulmonary fibrosis * peripheral neuropathy of National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade ≥1 * pregnant or breastfeeding patients * other serious diseases